Emergent BioSolutions
EBS
$4.70
Share price
-1.16%
Change (1 day)
-42.41%
Change (1 year)
Categories
P/S ratio for Emergent BioSolutions (EBS)
P/S ratio as of May 2024 (TTM): 0.2155
According to Emergent BioSolutions 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.215474. At the end of 2023 the company had a P/S ratio of 0.1216.
P/S ratio history for Emergent BioSolutions from 2006 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 0.1216 | -77.72% |
| 2022 | 0.5458 | -61.29% |
| 2021 | 1.41 | -57.23% |
| 2020 | 3.30 | 16.26% |
| 2019 | 2.84 | -34.1% |
| 2018 | 4.30 | -8.98% |
| 2017 | 4.73 | 22.78% |
| 2016 | 3.85 | -3.92% |
| 2015 | 4.01 | 32.41% |
| 2014 | 3.03 | -7.29% |
| 2013 | 3.26 | -3.47% |
| 2012 | 3.38 | 52.71% |
| 2011 | 2.21 | -22.84% |
| 2010 | 2.87 | 60.83% |
| 2009 | 1.78 | -59.21% |
| 2008 | 4.38 | 431.65% |
| 2007 | 0.8230 | -53.78% |
| 2006 | 1.78 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.97 | 1,278.57% | 🇺🇸 USA |
 Merck MRK | 5.34 | 2,378.91% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 2.43 | 1,028.71% | 🇬🇧 UK |
 Soligenix SNGX | 49.3 | 22,769.49% | 🇺🇸 USA |
 SIGA Technologies SIGA | 3.38 | 1,468.14% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 401 | 185,889.96% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | 1.19 | 452.46% | 🇮🇱 Israel |